Novartis said the European Medicines Agency has recommended its Kisqali cancer drug for market authorization. The drugmaker said Friday that the EMA's Committee for Medicinal Products for Human ...

What if we would have watched it for six months? Like, I possibly couldn’t be here talking to you and have lived my life six ...

In May 2024, Google DeepMind released AlphaFold 3, a game changing protein folding model that predicts with 50% better ...

Novartis NVS announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (EMA) recommended granting approval to the breast cancer drug Kisqali ...

Novartis NVS announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (EMA ...

Novartis posted third-quarter results that beat analysts' estimates and raised its full-year outlook, buoyed by strong sales ...

Narasimhan is confident that Novartis will achieve its goal of increasing sales by an average of 5% annually by 2028.

Novartis exceeded analyst expectations in the third quarter, driven primarily by the strong U.S. sales of Cosentyx, as well ...

Novartis reported strong third-quarter sales of $12.823 billion, beating consensus, with key growth drivers contributing to momentum and upgraded guidance for 2024.